Daniel O'Day, Gilead CEO (Alex Brandon/AP Images)
Gilead's strong HIV business balances out low Covid and cancer drug sales
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the same amount of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
